DIASORIN S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.7 EUR | 0.00% |
|
+0.05% | +8.00% |
| Jun. 05 | Mib up at start, DiaSorin good on FDA news | AN |
| Jun. 05 | US FDA clears Diasorin's Liaison Plex Yeast Blood Culture Assay | AN |
| Sales 2024 * | 1.19B 1.29B | Sales 2025 * | 1.28B 1.39B | Capitalization | 5.37B 5.84B |
|---|---|---|---|---|---|
| Net income 2024 * | 192M 209M | Net income 2025 * | 216M 235M | EV / Sales 2024 * | 5.11 x |
| Net Debt 2024 * | 697M 759M | Net Debt 2025 * | 511M 557M | EV / Sales 2025 * | 4.61 x |
| P/E ratio 2024 * |
30.3
x | P/E ratio 2025 * |
26.2
x | Employees | 3,209 |
| Yield 2024 * |
0.9% | Yield 2025 * |
1.05% | Free-Float | 37.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on DiaSorin S.p.A.
More press releases
More news
| 1 week | -0.05% | ||
| Current month | +1.78% | ||
| 1 month | +9.43% | ||
| 3 months | +8.23% | ||
| 6 months | +15.30% | ||
| Current year | +8.00% |
1 week
97.84
101.20
1 month
91.28103.55
Current year
82.72103.55
1 year
81.24103.55
3 years
81.24208.80
5 years
81.24211.80
10 years
26.00211.80
| Managers | Title | Age | Since |
|---|---|---|---|
Carlo Rosa
CEO | Chief Executive Officer | 58 | 97-12-31 |
| Director of Finance/CFO | 53 | 10-12-31 | |
| Director/Board Member | 61 | 99-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 22-04-28 | |
Carlo Rosa
CEO | Chief Executive Officer | 58 | 97-12-31 |
| Director/Board Member | 61 | 99-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.76% | 14 M€ | -3.05% | ||
| 0.69% | 5 M€ | +12.55% | ||
| 0.17% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 100.7 | +0.20% | 66,829 |
| 24-06-05 | 100.5 | +1.01% | 74,454 |
| 24-06-04 | 99.5 | +0.10% | 95,242 |
| 24-06-03 | 99.4 | +0.46% | 98,094 |
| 24-05-31 | 98.94 | -1.70% | 208,590 |
Real-time Borsa Italiana, June 06, 2024 at 11:44 am EDT
More quotes
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc.
At the end of 2023, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.
Calendar
2024-06-18
- Mediobanca Italian CEO Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
100.7
EUR
Average target price
101.7
EUR
Spread / Average Target
+0.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.00% | 5.82B | |
| -5.12% | 8.16B | |
| +31.71% | 5.72B | |
| -12.56% | 4.01B | |
| +12.16% | 2.75B | |
| -59.74% | 2.66B | |
| -5.70% | 2.39B | |
| +16.51% | 2.05B | |
| -7.86% | 1.82B | |
| -5.17% | 1.49B |
- Stock Market
- Equities
- DIA Stock
